9/22/2025

Merck trades at a deep discount to peers with strong profitability, Keytruda-led growth, and a 3.99% yield despite near-term risks. See why MRK stock is a strong buy.

Source: SeekingAlpha

9/21/2025

Discover AQR Capital's latest Q2 2025 portfolio moves—top holdings, stake increases, and insights on their quantitative investment strategy.

Source: SeekingAlpha

9/20/2025

The Undercovered Dozen is a weekly Seeking Alpha editor-curated series highlighting 12 articles on lesser-covered stocks from the previous seven days.

Source: SeekingAlpha

9/20/2025

A high yield is only one part of the story when it comes to picking dividend stocks.

Source: Yahoo

9/20/2025

Merck & Co., Inc. (NYSE:MRK) is included among the 13 Best High Dividend Stocks to Buy Under $100. Merck & Co., Inc. (NYSE:MRK) ranks among the largest pharmaceutical companies in the world. Drug discovery is a difficult and unpredictable process, and at present, investors are worried that the company’s existing patents may expire before it […]

Source: Yahoo

9/19/2025

RAHWAY, N.J., September 19, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration in adults across most solid tumor indications for KEYTRUDA® (pembrolizumab). Berahyaluronidase alfa is a variant of human hyaluronidase developed and manufactured by Alteogen Inc. KEYTRUDA QLEX must be administ

Source: Yahoo

9/19/2025

Source: SeekingAlpha

9/19/2025

Merck eyes new launches like Capvaxive and Winrevair, among others, to drive long-term growth as Keytruda nears loss of exclusivity.

Source: Yahoo

9/19/2025

Bristol Myers ramps up a $2.5B restructuring plan to cut costs, streamline operations, and offset pressure from generic competition.

Source: Yahoo

9/19/2025

Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.

Source: Yahoo

9/19/2025

RAHWAY, N.J., September 19, 2025--Merck Receives Positive EU CHMP Opinion for ENFLONSIA™ (clesrovimab) for the Prevention of RSV in Infants During Their First RSV Season

Source: Yahoo

9/19/2025

RAHWAY, N.J., September 19, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted two positive opinions for KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. One recommends approval of a new subcutaneous (SC) route of administration and a new pharmaceutical form (solution for injection) for KEYTRUDA® (pembrolizumab), which if approved would be marketed i

Source: Yahoo

9/19/2025

AstraZeneca is a leading global pharmaceutical company with strong growth in oncology, diversified revenues, and a robust pipeline. Click to read why AZN is a Buy.

Source: SeekingAlpha

9/19/2025

Several market-altering decisions are on the agency’s docket for the rest of 2025.

Source: Yahoo

9/19/2025

Merck announces that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted two positive opinions for Keytruda , its anti-PD-1 treatment.The first opinion...

Source: Finnhub

9/18/2025

As major U.S. indices hit record highs, driven by a surge in technology stocks and strategic investments, the market continues to present intriguing opportunities for investors. In this dynamic environment, dividend stocks remain an attractive option for those seeking steady income and potential growth amid fluctuating interest rates and evolving economic conditions.

Source: Yahoo

9/18/2025

Nanobiotix S.A. stock surges on promising cancer trial results and major partnership. Click for more on NBTX stock and why I'm bullish on this microcap.

Source: SeekingAlpha

9/18/2025

Novo Nordisk A/S is a strong buy for 2024, with cutting-edge drug approvals, cost savings, and robust long-term growth potential. Click for my NVO stock update.

Source: SeekingAlpha

9/17/2025

Netflix upgraded, Five Below initiated: Wall Street's top analyst calls

Source: Yahoo

9/17/2025

Progress in RNA-based medicines, immunotherapies and targeted treatments is not simply desirable, it is a critical necessity. Deadly cancers such as glioblastoma and pancreatic cancer remain among the hardest to treat, while rare pediatric disorders still take a tragic toll on young patients each year. Against this backdrop of significant unmet need, Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile) distinguishes itself. Guided by the forward-looking leadership of chair and CEO Dr. Vuong Trieu

Source: Yahoo